Bank says Demant prognosis probably affected by component shortages
Uncertainties about the lack of components and transportation as well as increased investments are contributing factors dampening the profit outlook for Demant’s 2022, says analyst at Danish bank Sydbank.
by marketwire, translated by daniel pedersen
Demant has released its expectations for 2022, including an organic growth of 5–9 percent and an EBIT result of DKK 3.4–3.7bn (USD 521–567m), in connection with the full-year financial figures for 2021 on Tuesday.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.